LONDON, April 8, 2014 /PRNewswire/ --
The trading session on Monday, April 07,
2014 ended on a lower note as the S&P 500 finished the
session 1.08% lower at 1,845.04 and the NASDAQ Composite closed at
4,079.75, down 1.16%. The Dow Jones Industrial Average finished at
16,245.87, down 1.02%. During the session, nine out of ten sectors
ended the session in negative. The S&P 500 Health Care Sector
Index finished the day at 664.68, down 1.06%, and the same has
declined 2.85% in the previous three trading sessions.
Investor-Edge has initiated coverage on the following equities:
Sanofi (NYSE: SNY), Impax Laboratories Inc. (NASDAQ: IPXL), Keryx
Biopharmaceuticals Inc. (NASDAQ: KERX) and Rigel Pharmaceuticals
Inc. (NASDAQ: RIGL). Free technical research on SNY, IPXL, KERX and
RIGL can be downloaded upon signing up at:
http://www.investor-edge.com/902-register
On Monday, Sanofi's stock advanced 1.15%, to close the day at
$51.82. The stock recorded a trading
volume of 3.26 million shares as compared with its three months
average volume of 1.81 million shares. The stock oscillated between
$51.28 and $51.93 during the trading
session. Sanofi's stocks have fallen by 0.38% in the previous three
trading sessions, 0.21% in the last one month, and 3.37% on YTD
basis. The stock is trading above its 50-day and 200-day moving
averages. Sanofi's 200-day moving average of $51.05 is above its 50-day moving average of
$50.53. Moreover, shares of the
company have a Relative Strength Index (RSI) of 49.51. Sign up
today to read free research on SNY at:
http://www.investor-edge.com/902-SNY-08Apr2014.pdf
Shares in Impax Laboratories Inc. reported a trading volume of 0.87
million shares, as compared with its three months average volume of
0.58 million shares. The stock ended the day at $23.81, up 0.89% and at an intraday range of
$23.02 and $24.38. Impax Laboratories Inc.'s shares have
declined 9.26% in the previous three trading sessions, 13.26% in
the last one month, and 5.29% on YTD basis. Shares of the company
traded at a PE ratio of 24.67. The stock is trading above its
200-day moving average. Impax Laboratories Inc.'s 50-day moving
average of $25.10 is above its
200-day moving average of $22.53.
Furthermore, the shares of the company have an RSI of 36.39. Sign
up today to read free research on IPXL at:
http://www.investor-edge.com/902-IPXL-08Apr2014.pdf
On Monday, Keryx Biopharmaceuticals Inc.'s stock finished the
session 0.75% lower at $15.80. A
total of 2.60 million shares were traded, which is below its three
months average volume of 3.24 million shares. The stock fluctuated
between $15.29 and $16.54 during the
session. Keryx Biopharmaceuticals Inc.'s stock have plummeted 7.22%
in the previous three trading sessions, while the same has advanced
3.47% in the last one month, and 22.01% on YTD basis. The stock is
trading above its 50-day and 200-day moving averages. Keryx
Biopharmaceuticals Inc.'s 50-day moving average of $15.65 is above its 200-day moving average of
$11.87. Moreover, shares of the
company have an RSI of 50.81. Sign up today to read free research
on KERX at:
http://www.investor-edge.com/902-KERX-08Apr2014.pdf
Shares in Rigel Pharmaceuticals Inc.'s registered a trading volume
of 1.37 million shares, as compared with its three months average
volume of 0.97 million shares. The stock ended the day at
$3.49, down 1.69% after vacillating
between $3.35 and $3.60. Rigel
Pharmaceuticals Inc.'s shares have declined 8.40% in the previous
three trading sessions, 22.79% in the last one month, but the same
has gained 22.46% on YTD basis. The stock is trading above its
200-day moving average. Rigel Pharmaceuticals Inc.'s 50-day moving
average of $3.68 is above its 200-day
moving average of $3.39.
Additionally, shares of the company have an RSI of 39.80. Sign up
today to read free research on RIGL at:
http://www.investor-edge.com/902-RIGL-08Apr2014.pdf
EDITOR'S NOTES:
1. This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a
best efforts basis and reviewed by Namrata
Maheshwari, a CFA charterholder. However, we are only human
and are prone to make mistakes. If you notice any errors or
omissions, please notify us below.
3. This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at
compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage
on your company? Send us a full investors' package to research [at]
http://www.investor-edge.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis.
This document, article or report is prepared and authored by
Investor-edge. An outsourced research services provider represented
by Namrata Maheshwari, CFA, has only
reviewed the information provided by Investor-edge in this article
or report according to the Procedures outlined by Investor-edge.
Investor-edge is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the
articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or
otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Investor-edge
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Investor-edge expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Investor-edge does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the
information. The included information is subject to change without
notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Investor-Edge